CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.…
CapsoVision (CV) Q3 2026 Earnings Call Transcript
CapsoVision (NASDAQ: CV) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 99 employees.
The shares were at 6.110 USD on 20 November 2026, up 14.6% over 52 weeks. Its 52-week range is 4.500 USD to 15.37 USD: the price is 60.2% below the high and 35.8% above the low.
Its market capitalisation is 327.56M USD.
CapsoVision reports return on equity of -190.9%, an operating margin of -209.5% and revenue up 0.8% year over year.
It holds more cash than debt, a net cash position of 20.98M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 9.500 USD is 55.5% above the current price. The next earnings report is expected on 25 March 2027.